Disease · MONDO_0016681
gliosarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. gliosarcoma. Diseases, record MONDO_0016681. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016681
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- glioblastoma with a sarcomatous component, glioblastoma with sarcomatous component
- Open Targets
Drugs65
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 38 | 38 | 38 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 18 | 18 | 18 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| GUANINE | CHEMBL219568 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DIANHYDROGALACTITOL | CHEMBL3137322 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ERLOTINIB HYDROCHLORIDE | CHEMBL1079742 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TASADENOTUREV | CHEMBL3990045 | Phase 2 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
1 to 10 of 65
See all 65 drugsTargets149
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 6 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| HDAC1 | Histone deacetylase | 4 | Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC2 | Histone deacetylase | 4 | Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3066 | Drugs and targets |
| HDAC3 | Histone deacetylase | 4 | Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/8841 | Drugs and targets |
| HDAC6 | Histone deacetylase | 4 | Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10013 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
1 to 10 of 149
See all 149 targetsTrials77
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00304031 | Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Phase 3 | 1,173 | 2014-04-30 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | Phase 3 | 637 | 2016-10-12 | Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma | BEVACIZUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | Phase 2 | 137 | 2017-02-27 | Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma | BEVACIZUMAB, TREBANANIB | Its record names the disease | ClinicalTrials.gov |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | Phase 2 | 125 | 2013-01-18 | Glioblastoma, Gliosarcoma, Brain Tumor | BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Phase 1/2 | 125 | 2015-05-13 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | TEMOZOLOMIDE, VORINOSTAT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | Phase 2 | 123 | 2013-05-01 | Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm | BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors | Phase 1/2 | 119 | 2015-03-02 | Glioblastoma Multiforme, Gliosarcoma | TEMOZOLOMIDE, VANDETANIB | Its record names the disease | ClinicalTrials.gov |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Phase 1/2 | 118 | 2013-05-17 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | MOTEXAFIN GADOLINIUM, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00720356 | Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Phase 2 | 115 | 2018-10-26 | Brain and Central Nervous System Tumors | BEVACIZUMAB, ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Phase 1/2 | 96 | 2016-09-23 | Malignant Glioma, Recurrent Glioblastoma | BEVACIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 77
See all 77 trialsComparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Randomized Arm 1: TMZ+RT + Placebo vs Randomized Arm 2: TMZ+RT + Bevacizumab: Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0 | 87 of 300 | 97 of 303 | 603 | NCT00884741 | Trial comparisons |
| Arm I (Bevacizumab and Temozolomide) vs Arm II (Bevacizumab and Irinotecan Hydrochloride): serious adverse events | 37 of 60 | 37 of 57 | 117 | NCT00433381 | Trial comparisons |
| Cohort 2: Bevacizumab+Placebo vs Cohort 2: Bevacizumab+AMG 386: Incidence of Grade 3+ Treatment-related Toxicity, Measured by CTCAE v. 4 (Cohort 2) | 21 of 57 | 20 of 57 | 114 | NCT01609790 | Trial comparisons |
| Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib vs Phase II-Arm A Pts (Control Group): RT + TMZ: serious adverse events | 52 of 82 | 15 of 30 | 112 | NCT00441142 | Trial comparisons |
| Conventional Adjuvant TMZ vs Dose-dense Adjuvant TMZ: Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4 | 7 of 51 | 13 of 40 | 91 | NCT00304031 | Trial comparisons |
| Conventional Adjuvant TMZ vs Dose-dense Adjuvant TMZ: Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4 | 5 of 51 | 11 of 40 | 91 | NCT00304031 | Trial comparisons |
| Efficacy Group vs Safety Lead-in Group: serious adverse events | 32 of 59 | 7 of 15 | 74 | NCT00525525 | Trial comparisons |
| Stage 1: Dasatinib 200mg/Day vs Stage 1B: Dasatinib up to 400mg/Day: Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS) | 1 of 21 | 2 of 29 | 50 | NCT00423735 | Trial comparisons |
| Stage 1: Dasatinib 200mg/Day vs Stage 1B: Dasatinib up to 400mg/Day: serious adverse events | 8 of 21 | 14 of 29 | 50 | NCT00423735 | Trial comparisons |
| Phase 1 Dose Escalation - Romidepsin vs Phase 2 Dose From Phase 1 - Romidepsin: serious adverse events | 0 of 8 | 0 of 40 | 48 | NCT00085540 | Trial comparisons |
1 to 10 of 22
See all 22 comparisons in its trialsPapers from its trials35
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016681
GET https://conductscience.org/api/diseases/v1/MONDO_0016681/drugs?page=2